Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-101 with Enzalutamide in Metastatic Prostate Cancer
NCT04033328Phase 1Terminated
- Sponsor
- ORIC Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORIC-101 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 12 months, Prostate Specific Antigen Response Rate at 36 months and 5 more. Started Oct 2019; status: terminated.
02
Drugs
ORIC-101
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04033328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033328.